Press release
Liposarcoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Stay ahead in the competitive pharmaceutical landscape with in-depth Liposarcoma Pipeline Insights! Discover the latest advancements, key Liposarcoma Companies driving innovation, and the most promising Emerging Drugs shaping the future of treatment. Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Liposarcoma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/liposarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Liposarcoma Pipeline Report
* In March 2025 , an open-label, non-randomized, multicenter trial enrolled patients with locally advanced or metastatic soft tissue sarcoma who had experienced disease progression within six months prior to enrollment.
* DelveInsight's Liposarcoma pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Liposarcoma treatment.
* The leading Liposarcoma Companies such as Boehringer Ingelheim, Ascentage Pharma Group Inc., Edgewood Oncology Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Salarius Pharmaceuticals, LLC, Lamassu Bio Inc., Pfizer, Valo Therapeutics Oy, OncoResponse, Inc., Adaptimmune, Incyte Corporation, Daiichi Sankyo, Numab Therapeutics AG, HRYZ Biotech Co., Sotio Biotech Inc . and others.
* Promising Liposarcoma Therapies such as MGCD516, Mirdametinib, Palbociclib, Pazopanib, Efatutazone, Selinexor and others.
Uncover Liposarcoma groundbreaking developments in the drug pipeline with our latest report! Gain exclusive insights into Liposarcoma Clinical Trials, regulatory updates, and Emerging Drugs across multiple therapeutic areas. Learn how leading Liposarcoma Companies are positioning themselves for success in the evolving pharmaceutical market-access the full report today!" @ Liposarcoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/liposarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Liposarcoma Emerging Drugs Profile
* Brigimadlin: Boehringer Ingelheim
Brigimadlin is a potent, oral MDM2-p53 antagonist. Brigimadlin binds to MDM2 and blocks the MDM2-p53 interaction which prevents MDM2 from inactivating p53, thereby restoring p53 function. The MDM2 oncoprotein is a critical regulator of the tumor suppressor p53. Overexpression of MDM2 promotes p53 degradation and aids tumor proliferation. Preclinical study results have shown that brigimadlin had single-agent efficacy in MDM2-amplified DDLPS PDX models and improved responses/disease control in patient-derived xenografts and syngeneic mouse tumor models. Currently, the drug is in Phase III stage of its development for the treatment of Liposarcoma.
* APG-115: Ascentage Pharma Group Inc.
APG-115 is an orally administered, selective, small-molecule inhibitor of the MDM2-p53 PPI. APG-115 has strong binding affinity to MDM2 and is designed to activate p53 tumor suppression activity by blocking the MDM2-p53 PPI. Preclinical studies demonstrated that APG-115 promoted the production of proinflammatory cytokines in T cells, enhanced CD4+ T cell activation, and increased PD-L1 expression on various tumor cells. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Liposarcoma.
* CAR-GPC3 T Cells: Sotio Biotech Inc.
CAR-GPC3 T Cells, uniquely combine the GOT2 transgene of the proprietary BOXR platform, a critical enzyme involved in cellular metabolism, with CAR T technology targeting GPC3-expressing tumors. BOXR1030 is a next generation CAR T cell therapy which benefits from its enhanced T cell metabolism in the solid tumor microenvironment. CAR-GPC3 T Cells have demonstrated strong preclinical evidence in models that simulated the solid tumor microenvironment. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Liposarcoma.
* BTX-A51: Edgewood Oncology Inc.
BTX-A51 is a first-in-class, small molecule, multi-kinase inhibitor of casein kinase 1 alpha (CK1), cyclin-dependent kinase 7 (CDK7) and CDK9 that synergistically co-targets master regulators of cancer to promote programmed cell death, or apoptosis. BTX-A51 has shown preclinical efficacy in treating patient-derived LPS in cell lines and human xenograft models and provides insight into the synergy gained by inhibiting both CK1a and CDK9. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Liposarcoma.
The Liposarcoma Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Liposarcoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Liposarcoma Treatment.
* Liposarcoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Liposarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Liposarcoma market.
Explore the dynamic world of drug development with our latest Liposarcoma Pipeline Insights report! From early-stage research to late-phase Liposarcoma Clinical Trials, our analysis covers key Liposarcoma Companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don't miss this opportunity to stay informed-download now! @ Liposarcoma Treatment Drugs [https://www.delveinsight.com/sample-request/liposarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Liposarcoma Companies
Boehringer Ingelheim, Ascentage Pharma Group Inc., Edgewood Oncology Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Salarius Pharmaceuticals, LLC, Lamassu Bio Inc., Pfizer, Valo Therapeutics Oy, OncoResponse, Inc., Adaptimmune, Incyte Corporation, Daiichi Sankyo, Numab Therapeutics AG, HRYZ Biotech Co., Sotio Biotech Inc and others.
Liposarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravitreal
* Subretinal
* Topical
Liposarcoma Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
The future of medicine is evolving rapidly! Get detailed insights into ongoing Liposarcoma Clinical Trials, major Companies driving innovation, and the most anticipated Emerging Drugs in the pipeline. Stay updated with the latest Liposarcoma Pipeline Insights-download our report for a deep dive into the next generation of therapeutics! @ Liposarcoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/liposarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Liposarcoma Pipeline Report
* Coverage- Global
* Liposarcoma Companies- Boehringer Ingelheim, Ascentage Pharma Group Inc., Edgewood Oncology Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Salarius Pharmaceuticals, LLC, Lamassu Bio Inc., Pfizer, Valo Therapeutics Oy, OncoResponse, Inc., Adaptimmune, Incyte Corporation, Daiichi Sankyo, Numab Therapeutics AG, HRYZ Biotech Co., Sotio Biotech Inc. and others.
* Liposarcoma Therapies- MGCD516, Mirdametinib, Palbociclib, Pazopanib, Efatutazone, Selinexor and others.
* Liposarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Liposarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which Liposarcoma Emerging Drugs are set to revolutionize treatment landscapes? Which Liposarcoma Companies are leading the way in drug discovery? Find answers in our latest Liposarcoma Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!" @ Liposarcoma Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/liposarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Liposarcoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Liposarcoma - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Brigimadlin: Boehringer Ingelheim
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase I/II)
* APG-115: Ascentage Pharma Group Inc.
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* BTX-A51: Edgewood Oncology Inc.
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Liposarcoma Key Companies
* Liposarcoma Key Products
* Liposarcoma- Unmet Needs
* Liposarcoma- Market Drivers and Barriers
* Liposarcoma- Future Perspectives and Conclusion
* Liposarcoma Analyst Views
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=liposarcoma-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Liposarcoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 3899923 • Views: …
More Releases from ABNewswire
Tech Pioneer Anno Robot: Over 70 Patents Drive Global Expansion of AI Coffee Mac …
In the rapidly evolving landscape of autonomous retail, one name consistently emerges as a beacon of innovation and technological prowess: Anno Robot. Established in 2017 in Shenzhen, a global hub for high-tech enterprises, Anno Robot has swiftly cemented its position as a National High-Tech Enterprise specializing in AI-driven commercial unmanned retail solutions. With a strategic focus on desktop robotic arms and intelligent vending kiosks, the company has not only addressed…
Sarcopenia Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Anal …
The Key Sarcopenia Companies in the market include - TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirscience Therapeutics, Turn Biotechnologies, NMD PHARMA, ImmunoForge, Dong Wha PHARM, and others.
DelveInsight's "Sarcopenia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Sarcopenia, historical and forecasted epidemiology as well as the Sarcopenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom…
Ovarian Cancer Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evalu …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Ovarian Cancer pipeline constitutes 180+ key companies continuously working towards developing 200+ Ovarian Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Ovarian Cancer Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ovarian Cancer Market.
The Ovarian Cancer Pipeline report…
Actinium Pharmaceuticals Advances Trop-2 Targeted Alpha Radiotherapy Into Phase …
Actinium Pharmaceuticals (NYSE American: ATNM) is advancing its Trop-2-targeted ATNM-400 construct into Phase 1/2 trials across the United States and Australia, marking an important step as the company broadens its presence in solid-tumor radiopharmaceuticals. With targeted alpha radiotherapy gaining momentum worldwide, the program reinforces Actinium's position as one of the more established players developing actinium-225-based therapeutics for treatment-resistant and late-stage cancers.
Why Trop-2 Remains One of Oncology's Most Valuable Targets
Trop-2 has…
More Releases for Liposarcoma
Myxoid Round Cell Liposarcoma (MRCLS) Drug Market: An Overview
Myxoid Round Cell Liposarcoma (MRCLS) is a rare and aggressive form of cancer that arises from the fat cells of connective tissues. It primarily affects the soft tissues, including the limbs, trunk, and retroperitoneum, often leading to pain, swelling, and other debilitating symptoms. MRCLS is classified as a type of liposarcoma, a cancer that can appear in various forms, with the myxoid subtype being particularly distinct due to the presence…
Liposarcoma Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Liposarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Liposarcoma, historical and forecasted epidemiology as well as the Liposarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Liposarcoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Liposarcoma market size from 2019 to 2032, segmented…
Retroperitoneal Liposarcoma Treatment Market - Size, Outlook, and Opportunity An …
Retroperitoneal liposarcoma (RLS) is a rare, biologically heterogeneous cancer, which occurs in retroperitoneum, lining of the abdominal space that covers the abdominal organs. Retroperitoneal liposarcoma grow continuously and may not get diagnosed until they are very large thus, its prognosis is poor compared to the other subtypes of retroperitoneal sarcomas. The reason for the development of these tumors are still unknown, however, genetic mutation is considered to be one of…
Liposarcoma Treatment Market to Register Steady Growth During 2022
Liposarcoma is a cancer of fat cells lying deep within the soft tissues, typically in retroperitoneum or thighs. According to WHO, liposarcoma is the most common type of sarcomas (cancer of soft tissue) and accounts for approximately 17-20% of all cases of sarcoma. However, WHO classifies liposarcoma in the rare diseases as the incidence rate of the disease is as low as 2.5 per Mn population. Liposarcoma most commonly occurs…
Global Liposarcoma Treatment Market to Record Sturdy Growth by 2022
Liposarcoma is a cancer of fat cells lying deep within the soft tissues, typically in retroperitoneum or thighs. According to WHO, liposarcoma is the most common type of sarcomas (cancer of soft tissue) and accounts for approximately 17-20% of all cases of sarcoma. However, WHO classifies liposarcoma in the rare diseases as the incidence rate of the disease is as low as 2.5 per Mn population. Liposarcoma most commonly occurs…
Future of Global Liposarcoma Treatment Market 2016 - 2022
Liposarcoma is a cancer of fat cells lying deep within the soft tissues, typically in retroperitoneum or thighs. According to WHO, liposarcoma is the most common type of sarcomas (cancer of soft tissue) and accounts for approximately 17-20% of all cases of sarcoma. However, WHO classifies liposarcoma in the rare diseases as the incidence rate of the disease is as low as 2.5 per Mn population. Liposarcoma most commonly occurs…
